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In Brief
Using a large-scale genome-wide
association study and exome
sequencing, we identified KIF5A as a
novel gene associated with ALS. Our data
broaden the phenotype resulting from
mutations in KIF5A and highlight the
importance of cytoskeletal defects in the
pathogenesis of ALS.
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(Affiliations continued on next page)SUMMARY
To identify novel genes associated with ALS, we un-
dertook two lines of investigation. We carried out a
genome-wide association study comparing 20,806
ALS cases and 59,804 controls. Independently, we
performed a rare variant burden analysis comparing
1,138 index familial ALS cases and 19,494 controls.
Through both approaches, we identified kinesin fam-
ily member 5A (KIF5A) as a novel gene associated
with ALS. Interestingly, mutations predominantly in
the N-terminal motor domain of KIF5A are causative
for two neurodegenerative diseases: hereditary
spastic paraplegia (SPG10) and Charcot-Marie-
Tooth type 2 (CMT2). In contrast, ALS-associated
mutations are primarily located at the C-terminal1268 Neuron 97, 1268–1283, March 21, 2018 ª 2018 Elsevier Inc.cargo-binding tail domain and patients harboring
loss-of-function mutations displayed an extended
survival relative to typical ALS cases. Taken together,
these results broaden the phenotype spectrum re-
sulting from mutations in KIF5A and strengthen the
role of cytoskeletal defects in the pathogenesis
of ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS; OMIM: 05400) is a neuro-
degenerative disorder clinically characterized by rapidly pro-
gressive muscle weakness and death due to respiratory
failure, typically within 2 to 4 years of symptom onset (van
Es et al., 2017). Although ALS is perceived as being rare,
approximately 6,000 Americans die annually from the condition
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across the globe will increase to nearly 400,000 in 2040, pre-
dominantly due to aging of the population (Arthur et al.,
2016). This increase is anticipated to place an enormous socio-
economic burden on global healthcare systems, in particular
because the annual healthcare cost per patient with ALS is
among the highest for any neurological disease (Gladman and
Zinman, 2015).Approximately 10% of ALS cases display a family history
(FALS), whereas the remaining 90% of ALS cases are sporadic
(SALS) in nature. Driven in large part by advances in genotyping
and sequencing technology, the genetic etiology of two-thirds of
FALS cases and about 10% of SALS cases is now known (Chia
et al., 2018; Renton et al., 2014). Mutations in SOD1were the first
identified cause of ALS (Rosen et al., 1993), contributing to
20% of FALS and 2% of SALS. More recently, pathogenicNeuron 97, 1268–1283, March 21, 2018 1271
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Figure 1. Identification of Association be-
tween KIF5A Locus and ALS Risk through
GWAS
(A) Manhattan plot showing p values from the
discovery set GWAS. Analysis of a combined set
of 20,806 cases and 59,804 controls is shown. The
dashed red line denotes the threshold for genome-
wide significance after multiple test correction
(p < 5.0 3 108). Five previously reported ALS-
associated loci are labeled in gray and one novel
loci, containing theKIF5A gene, is labeled in black.
(B) Regional association plot of the KIF5A locus.
Recombination rates are from HapMap phase 2
European ancestry samples. The R2 pattern
is based on the rs113247976 SNP using 85 Euro-
pean ancestry samples (CEU) from the November
2010 release of the 1000 Genomes Project data-
set. R2 of the p.Pro986Leu (rs113247976) with
additional SNPs achieving genome-wide sig-
nificance was 0.544 (rs117027576), 0.544
(rs118082508), 0.741 (rs116900480), and 0.347
(rs142321490).hexanucleotide repeat expansions located within the first intron
of the C9orf72 gene on chromosome 9p21 were identified as
the most common cause of both FALS (40%) and SALS
(7%) (DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Interestingly, this repeat expansion contributes to 10% of all
frontotemporal dementia (FTD) cases, thus genetically explain-
ing much of the overlap between these clinical syndromes
(Majounie et al., 2012). As a result of these major discoveries,
there are several ongoing efforts toward directed silencing of
these mutant genes, which could result in a therapeutic treat-
ment for up to 10% of all ALS cases and for a similar portion of
FTD cases.
In addition to the insights provided by each novel ALS gene,
the collective knowledge gained from genetic factors provides
a more comprehensive understanding of the interacting path-
ways underlying motor neuron degeneration. For example, the
identification of ALS genes has revealed at least three pathways
believed to contribute to the development of ALS: (1) RNAmeta-
bolism (based on the observation of mutations in C9orf72, TDP-
43, FUS, HNRNPA1, and MATR3), (2) protein homeostasis
(UBQLN2, VCP, OPTN, and VAPB), and (3) cytoskeletal dy-
namics (PFN1, TUBA4A, and DCTN1) (Chia et al., 2018; Robber-
echt and Eykens, 2015; Taylor et al., 2016). Understanding the
mechanisms leading to disease pathogenesis again provides
targets for therapeutic intervention that may be applicable to
all forms of ALS.
Due to the decreased accessibility of multiple affected family
members with unknown genetic etiology, there has been an
increased focus on the identification of ALS-associated genes
with moderate to low impact. Despite their lower effect, such1272 Neuron 97, 1268–1283, March 21, 2018genes continue to provide valuable
insight into ALS pathogenesis. For
example, the product of the risk factor
TBK1 is known to interact with the prod-
uct of ALS-associated gene OPTN,
further solidifying the role of autophagyand protein homeostasis in disease development (Cirulli et al.,
2015; Freischmidt et al., 2015; Maruyama et al., 2010; Morton
et al., 2008). Similarly, the risk factor NEK1, identified through
a rare variant burden analysis (RVB) of index FALS (i.e.,
one affected sample per family), is a known binding partner
ofC21orf2, an ALS risk factor found through genome-wide asso-
ciation studies (GWASs) (Cirulli et al., 2015; Kenna et al., 2016;
Malovannaya et al., 2011; van Rheenen et al., 2016). The interac-
tion of these two proteins is required for efficient DNA damage
repair (Fang et al., 2015), a pathway that is becoming increas-
ingly implicated as a contributing factor in ALS and other
neurodegenerative diseases (Coppede` and Migliore, 2015;
Lopez-Gonzalez et al., 2016; Madabhushi et al., 2014; Wang
et al., 2013).
RESULTS
GWASs Identify KIF5A as a Novel ALS-Associated Gene
To identify new susceptibility loci operating in ALS, we undertook
a large-scale GWAS involving 12,663 patients diagnosed with
ALS and 53,439 control subjects (Tables S1 and S2). Our data
were then incorporated into a meta-analysis with a recently pub-
lished GWAS involving 12,577 ALS cases and 23,475 control
subjects (van Rheenen et al., 2016). After imputation and qual-
ity-control measures (see STAR Methods and Figure S1 for the
workflow and Figure S2 for the multidimensional scaling plot),
10,031,630 genotyped and imputed variants from 20,806 ALS
cases and 59,804 control samples were available for association
analysis (Figure 1A). Quantile-quantile plots did not show evi-
dence of significant population stratification (l1000 = 1.001;
Figure S3). SNPs achieving genome-wide significance (p < 5.03
108) are listed in Tables 1 and S3 and suggestive loci with SNPs
associated at p < 5.0 3 107 are listed in Table S4.
Our analysis revealed five previously identified loci that
achieved genome-wide significance (loci including TNIP1,
C9orf72, TBK1, UNC13A, and C21orf2) (Benyamin et al., 2017;
Laaksovirta et al., 2010; Shatunov et al., 2010; van Es et al.,
2009; van Rheenen et al., 2016). In addition, we observed a
strong association signal for five SNPs in linkage disequilibrium
on chromosome 12q14.1 that reached genome-wide statistical
significance spanning a region of several hundred kilobases
(Table 1; Figure 1B). Of the five SNPs, two of them resided in
close proximity to each other within a large intergenic region
and two in proximity to short-chain dehydrogenase/reductase
family 9C member 7 (SDR9C7), a gene expressed primarily in
skin. However, one SNP (rs113247976) results in a p.Pro986Leu
coding change within the kinesin family member 5A (KIF5A) gene
(p = 6.4 3 1010, odds ratio [OR] = 1.38, 95% CI = 1.24–1.53;
Figure 2). The case:control allele frequencies for the combined
discovery cohort were 2.07%:1.55% and genotype counts
were 5: 529: 12,043 to 7: 786: 22,682 (homozygotes alternative
allele: heterozygotes: homozygous reference allele; Figure 2).
Calculations based on our cohort size as well as the OR and
allele frequency of rs113247976 result in an 99.5% power to
detect this as an ALS-associated SNP.
Rare Variant Burden Analysis Identifies KIF5A as an
ALS Gene
In an independent line of investigation, we attempted to identify
novel ALS genes through exome-wide RVB. In brief, RVB com-
pares the frequency of variants within each gene below a user-
defined frequency threshold in a case-control cohort. As the
last two ALS-associated genes identified by this methodology
(TBK1 and NEK1) displayed an increased frequency of loss-of-
function (LOF) variants, we focused our initial analysis on such
variants (consisting of nonsense and predicted splice altering)
(Cirulli et al., 2015; Freischmidt et al., 2015; Kenna et al., 2016).
Toward this end, we performed RVB testing for association of
LOF variants in a cohort of 1,138 index FALS cases and 19,494
controls, after applying quality-control filters (Experimental
Model and Subject Details; Figure S4; Tables S5 and S6). Genes
displaying p < 5.0 3 104 are shown in Table 2. The previously
identified ALS genes, TBK1 (p = 5.58 3 107, OR = 15.11,
95% CI = 5.81–38.69) and NEK1 (p = 1.68 3 106, OR = 6.64,
95% CI = 3.32–12.51), yielded strong associations with ALS,
reaching exome-wide significance (Figure 3). In addition, we
observed a single novel gene reaching exome-wide significance,
KIF5A (p = 5.55 3 107; OR = 32.07, 95% CI = 9.05–135.27).
Within this gene, we observed 6 LOF variants in our 1,138 cases
(0.53%) compared to 3 such variants in our comparison cohort of
19,494 controls (0.015%; Table 2). There was no evidence of
genomic inflation (l = 0.93; Figure S5), sequencing center
or other sub-cohort bias (Figure S6), or call rate bias (Fig-
ure S7) in our analysis. Of the index FALS cases carrying
KIF5A LOF mutations, we obtained DNA from two siblings of
the proband carrying a c.2993-3C>T, exon 27 - 50 splice junction
variant and from a sibling of a different proband carrying a
c.3020+2T>A, exon 27 - 30 splice junction variant. These variantssegregated with disease within each of these families. Sanger
sequencing validated all identified LOF variants containing sam-
ples in the discovery set and affected relatives.
Interestingly, whenwe investigated the location of the six ALS-
associated variants present in KIF5A, all occurred within a 34 bp
stretch of DNA and were predicted to affect splicing of exon 27,
which encodes amino acids 998–1007 (Table 3; Figure 4A). Five
of the six variants were located on sequential base pairs on the 30
end of the exon, whereas one was located on the 50 end of the
exon. We used the application ASSEDA (Automated Splice
Site and Exon Definition Analyses) to predict any mutant
mRNA splice isoforms resulting from these variants (Tompson
et al., 2007). This algorithm was chosen as it is known to have
high performance in splice prediction (Caminsky et al., 2014).
ASSEDA predicted a complete skipping of exon 27 for all vari-
ants, yielding a transcript with a frameshift at coding amino
acid 998, the deletion of the normal C-terminal 34 amino
acids of the cargo-binding domain, and the extension of an aber-
rant 39 amino acids to the C terminus (Table 3; Figures 4B and
4C). The presence of transcripts with skipped exon 27 was
demonstrated by performing RT-PCR in two patients carrying
exon 27 - 30 splice junction variants (c.3020+2T>A and
c.3020+1G>A) using RNA from lymphoblasts and peripheral
blood mononuclear cells, respectively. This splice form was
not detected in four control lines (Figure 4D). Sequence analysis
of the smaller RT-PCR products obtained from the patient cells
confirmed the exon 26–28 splicing event. Material for RT-PCR
was not available for any other patient carrying a KIF5A LOF
variant.
Our initial RVB was restricted to single nucleotide variants due
to the limited sensitivity and comparatively high false-positive
rates associated with identifying small insertions and deletions
(indels) within exome sequencing data (Fang et al., 2014). Based
on our discovery of increased LOF variants within KIF5A, we re-
evaluated this region for the presence of indels. Our analysis re-
vealed two (0.026%) indels within our cohort of 1,138 FALS
cases, compared to zero (0%) indels among 19,494 control sam-
ples. Both of these indels (p.Asp996fs and p.Asn999fs) resulted
in a frameshift of the KIF5A protein coding sequence, and were
located close to the splice junction variants that we previously
observed to cause skipping of exon 27, resulting in a frameshift
at amino acid 998 (Table 3). Sanger sequencing confirmed the
presence of both indels. Combining the results of the single
nucleotide and indel variant analysis yielded a highly significant
p of 3.8 3 109 (OR = 41.16, 95% CI = 12.61–167.57). We failed
to detect any signals of RVB association for rare missense
variants across KIF5A or within any sub-domain of the gene
(Table S8).
Replication Analysis of rs113247976 and LOF Variants
in KIF5A
Given the strong signal of the missense variant identified by
our GWAS (p.Pro986Leu, rs113247976) and its close proximity
to the LOF variants identified by our RVB (amino acids 996–
999), we attempted to replicate its association with ALS by
analyzing additional cohorts. To accomplish this, we evaluated
this variant in a cohort of 4,159 ALS cases and 18,650 controls
that were non-overlapping with our GWAS discovery analysisNeuron 97, 1268–1283, March 21, 2018 1273
Table 1. SNPs Achieving Genome-wide Significance in the Discovery GWAS
SNP Information Present Study (8,229 Cases/36,329 Controls)
Van Rheenen et al. (12,577 Cases/23,475
Controls)
Combined Discovery Set (20,806 Cases/
59,804 Controls)
SNP Chr Position Gene
Case
MAF
Control
MAF OR [95% CI] p
Case
MAF
Control
MAF OR [95% CI] p
Case
MAF
Control
MAF OR [95% CI] p
Novel Loci
rs117027576 12 57,316,603 KIF5A 1.55% 1.27% 1.45
[1.20–1.76]
1.1 3 104 1.98% 1.59% 1.33
[1.16–1.53]
4.3 3 105 1.81% 1.40% 1.37
[1.23–1.54]
2.3 3 108
rs118082508 12 57,318,819 KIF5A 1.56% 1.28% 1.45
[1.20–1.76]
1.0 3 104 1.98% 1.60% 1.33
[1.16–1.53]
3.8 3 105 1.81% 1.41% 1.37
[1.23–1.54]
2.0 3 108
rs113247976* 12 57,975,700 KIF5A 1.83% 1.42% 1.46
[1.23–1.74]
9.2 3 106 2.14% 1.70% 1.33
[1.17–1.52]
1.1 3 105 2.02% 1.53% 1.38
[1.24–1.53]
6.4 3 1010
rs116900480 12 58,656,105 KIF5A 1.75% 1.46% 1.42
[1.21–1.68]
1.9 3 105 2.08% 1.66% 1.34
[1.18–1.53]
7.1 3 106 1.95% 1.54% 1.37
[1.24–1.52]
6.6 3 1010
rs142321490 12 58,676,132 KIF5A 1.79% 1.48% 1.43
[1.21–1.68]
1.5 3 105 2.08% 1.66% 1.34
[1.18–1.53]
8.0 3 106 1.97% 1.55% 1.37
[1.24–1.52]
6.1 3 1010
Previously Published Loci
rs10463311 5 150,410,835 TNIP1 73.19% 74.84% 0.94
[0.89–0.98]
7.8 3 103 73.34% 75.79% 0.91
[0.87–0.94]
8.5 3 107 73.28% 75.21% 0.92
[0.89–0.95]
4.0 3 108
rs3849943 9 27,543,382 C9orf72 71.79% 76.31% 0.84
[0.80–0.88]
1.4 3 1012 72.78% 76.5% 0.83
[0.80–0.87]
4.0 3 1019 72.39% 76.38% 0.84
[0.81–0.86]
3.8 3 1030
rs74654358 12 64,881,967 TBK1 3.77% 4.01% 1.20
[1.07–1.34]
1.6 3 103 5.12% 4.61% 1.23
[1.13–1.34]
7.7 3 107 4.59% 4.25% 1.22
[1.14–1.30]
4.7 3 109
rs12973192 19 17,753,239 UNC13A 67.62% 69.37% 0.86
[0.82–0.91]
1.3 3 108 64.52% 66.00% 0.9
[0.87–0.93]
2.4 3 108 65.75% 68.05% 0.89
[0.86–0.91]
3.9 3 1015
rs75087725 21 45,753,117 C21orf2 0.70% 0.46% 1.99
[1.44–2.75]
2.2 3 105 1.83% 1.27% 1.61
[1.39–1.87]
8.7 3 1011 1.38% 0.78% 1.67
[1.46–1.91]
1.8 3 1014
Position is based on HumanGenome Assembly build 37. Nearest gene or previously published gene names are included. Chr, chromosome; MAF,minor allele frequency; OR, odds ratio; 95%CI,
confidence interval; *rs113247976 represents the p.Pro986Leu variant in KIF5A (GenBank: NM_004984.2).
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Figure 2. Discovery and Replication of the Association of the KIF5A p.Pro986Leu (rs113247976) Variant with ALS
Analysis of the p.Pro986Leu (rs113247976) variant within each of the described cohorts is shown. Allelic association for all subcohorts was analyzed by logistic
regression followed by a fixed-effects meta-analysis. The Forest plot (right) displays the distribution of OR estimates across study cohorts with the vertical gray
line denoting the OR estimated under the meta-analysis, and with the width of the horizontal lines and the diamonds corresponding to 95% confidence intervals.(STARMethods; Figure S8). This included non-overlapping sam-
ples from our RVB (673 FALS and 17,696 controls). Analysis of
the cohort revealed an allele frequency of 1.78% in cases and
1.32% in controls (rs113247976, p = 3.82 3 104, OR = 1.42,
95% CI = 1.17–1.70), thereby replicating the association of the
original GWAS. A meta-analysis of the GWAS and replication
cohort (n = 24,965 cases and 78,454 controls) yielded a highly
significant p of 7.09 3 1013 (OR = 1.39, 95% CI = 1.33–1.45;
Figure 2). These results support the association of KIF5A
p.Pro986Leu with ALS. However, at this point we cannot defi-
nitely state that the missense variant is the primary risk factor,
as we cannot rule out other variants in linkage disequilibrium.
We next performed mutational screening of KIF5A in an addi-
tional cohort of 9,046 ALS cases that had not been included in
our original RVB. This revealed three additional carriers of C-ter-
minal variants. One sporadic patient harbored an exon 26 frame-
shift mutation (p.Asn997fs) and a second sporadic patient
harbored an exon 27 splice-altering mutation (c.2993-1G>A;
Table 3). The third patient carried a p.Arg1007Lys (c.3020G>A)
mutation and had a familial history of ALS. This mutation was
also observed in FALS patients from our RVB; however, a com-
parison of 240,715 common variant sites between the two pa-
tients failed to reveal a familial relationship (Experimental Model
and Subject Details). Additionally, one patient was observed toTable 2. Top ALS Associations Identified through RVB of FALS and
Gene FALS Control
KIF5A 6 (0.53%) 3 (0.02%)
TBK1 8 (0.70%) 9 (0.05%)
NEK1 12 (1.05%) 32 (0.16%)
CALHM2 7 (0.62%) 9 (0.05%)
COL14A1 8 (0.70%) 16 (0.08%)
AK1 10 (0.88%) 34 (0.17%)
ATRN 5 (0.44%) 9 (0.05%)
VLDLR 5 (0.44%) 9 (0.05%)
FUS 4 (0.35%) 4 (0.02%)
ZMYND12 6 (0.53%) 12 (0.06%)carry a predicted splice-altering variant proximal to exon 3
(c.291+5G>A). However, this variant was not supported as
creating an aberrant transcript by ASSEDA. The cohort used
for this analysis was comprised mainly of sporadic ALS cases.
LOF variants were not observed in a follow-up panel of 1,955
controls. Comparison of the LOF variants in sporadic patients
(2/9,046 cases, 0.022%)with either the 1,955 replication controls
or all controls analyzed in this study (21,449 controls) yielded
insignificant p values (0.868 and 0.423, respectively). Interest-
ingly, the frequency of LOF variants in sporadic cases is lower
than that observed in our original FALS cohort (0.703%), sug-
gesting that KIF5A LOF variants display a high penetrance.
Furthermore, the rate of LOF variants reported in the Exome
Aggregation Consortium (ExAC) database is lower than we
observed in the control samples used in our discovery cohort
(0.007% versus 0.015%).
ALS-Associated Mutations in KIF5A Are Distinct from
SPG10/CMT2 Mutations
Missense mutations within KIF5A are a known cause of heredi-
tary spastic paraparesis (spastic paraplegia type 10, autosomal
dominant; OMIM: 604187) and of Charcot-Marie-Tooth disease
type 2 (CMT2) (Crimella et al., 2012; Jennings et al., 2017; Liu
et al., 2014; Reid et al., 2002). Although SPG10 and CMT2 shareControl Exome Sequencing Results
OR p
32.07 (9.05–135.27) 5.55 3 107
15.11 (5.81–38.69) 5.58 3 107
6.64 (3.32–12.51) 1.68 3 106
12.13 (4.47–31.79) 9.19 3 106
8.04 (3.32–18.08) 2.72 3 105
5.37 (2.55–10.41) 5.62 3 105
11.06 (3.57–31.02) 1.66 3 104
10.87 (3.51–30.43) 1.79 3 104
16.53 (4.25–64.33) 2.08 3 104
7.92 (2.86–19.96) 2.61 3 104
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Figure 3. Identification of Association be-
tween KIF5A and ALS Risk through Rare
Variant Burden Analysis of Exome Se-
quencing
Manhattan plot showing gene-level p values from
an exome-wide rare variant burden analysis. Ana-
lyses of 1,138 index FALS cases versus 19,494
controls were restricted to rare LOF variants (splice
altering/nonsense, MAF < 0.001). A minimum of
three LOF variant carriers were required for anal-
ysis. The dashed red line denotes the threshold for
exome-widesignificanceafter correction for 11,472
genes (4.36 3 106). Previously reported (gray)
and novel (black) genes exhibiting a significant
excess of rare LOF variants in patients are shown.clinical features with ALS, a careful examination of the clinical re-
cords of the ALS cases with LOF mutations in KIF5A ruled out
misdiagnosis. Furthermore, we detected no variants previously
associated with SPG10 or CMT2 in our FALS cohort (Liu
et al., 2014).
To further elucidate genotype-phenotype relationships, we
evaluated the location of mutations within KIF5A. Interestingly,
mutations contributing to SPG10 and to CMT2 are almost exclu-
sively missense changes and are located in the N-terminal motor
domain (amino acids 9–327) of KIF5A (Figure 5). In contrast, the
mutations identified as contributing to ALS are found predomi-
nantly in the C-terminal cargo-binding region of KIF5A (amino
acids 907–1032) with the highly penetrant FALS mutations
showing LOF. These results indicate that the functional domain
mutated in KIF5A dictates the clinical phenotype, resulting in
distinct yet overlapping neurodegenerative diseases.Table 3. LOF Variants within KIF5A Identified in Probands
Position Variant Exon cDNA Description
Control Variants
57,963,470 A>G 11 c.1117+4A>G 30 splice junction
57,966,423 C>T 15 c.1630C>T p.Arg544*
57,976,884 G>C 28 c.3021G>C 50 splice junction
FALS Variants
57,975,729 GA>A 26 c.2987delA p.Asp996fs
57,976,382 C>T 27 c.2993-3C>T 50 splice junction
57,976,385 GA>G 27 c.2996delA p.Asn999fs
57,976,411 A>G 27 c.3019A>G p.Arg1007Gly
57,976,412 G>A 27 c.3020G>A p.Arg1007Lys
57,976,412 G>A 27 c.3020G>A p.Arg1007Lys
57,976,413 G>A 27 c.3020+1G>A 30 splice junction
57,976,414 T>A 27 c.3020+2T>A 30 splice junction
57,976,415 A>G 27 c.3020+3A>G 30 splice junction
SALS Variants
57,957,481 G>A 3 c.291+5G>A 30 splice junction
57,975,731 CA>C 26 c.2989delA p.Asn997fs
57,976,384 G>A 27 c.2993-1G>A 50 splice junction
P, possible; Y, yes; N, no; M, male; F, female; L, limb onset; B, bulbar onset,
skipping based on frameshifts or nonsense mutations (Tompson et al., 200
1276 Neuron 97, 1268–1283, March 21, 2018Patients withKIF5A LOFMutations Display Younger Age
at Onset and Longer Survival
To establish the existence of any commonalities between pa-
tients with LOF mutations in the C-terminal region of KIF5A,
we evaluated their clinical phenotype. Cases with LOF muta-
tions exhibited a median age of onset at 46.5 years (n = 19;
Table S7). This is lower than the age of onset reported for ALS
in epidemiological studies (65.2 years, interquartile range
56.0–72.2) (Ahmeti et al., 2013). Interestingly, we also observed
an increased disease duration (survival) in patients harboring
these LOF mutations. The median survival time of ALS patients
is 20–36 months (Ahmeti et al., 2013). In contrast, cases with
LOF mutations exhibited a median survival of nearly 10 years
(117 months, n = 17; Table S7). ALS patients with symptom
onset before 40 years of age have been shown to have longer
survival, often exceeding 10 years (Chio` et al., 2009). In contrast,Predicted
Exon
Skipping Gender
Age of
Onset
(Years)
Site of
Onset
Survival
(Months)
Alive
(Yes/No)
P M n/a n/a n/a n/a
– F n/a n/a n/a n/a
N F n/a n/a n/a n/a
– M 45 n/a n/a n/a
Y M 29 L >264 Y
– M 42 L >12 Y
Y F 53 L 45 N
Y M 50 L >108 Y
Y F 50 n/a >240 Y
Y M 45 B >220 Y
Y M 46 B 124 N
Y M 50 B 54 N
N n/a n/a n/a n/a n/a
– F 50 L >96 Y
Y n/a 52 B n/a n/a
n/a, not available or applicable. Note that ASSEDA does not predict exon
7).
Consensus
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Figure 4. ALS-Associated LOF Variants of
KIF5A Disrupt C-Terminal Sequence by
Inducing Skipping of Exon 27
(A) Single nucleotide variants (SNVs) within KIF5A
identified in ALS patients are clustered at the
50 and 30 splice junctions of exon 27. The
consensus splice sequence is shown.
(B) ALS-associated SNVs are predicted to induce
skipping of exon 27 and result in an aberrant
mRNA transcript.
(C) The skipping of exon 27 of KIF5A yields an out-
of-frame and extended disrupted C-terminal
peptide sequence. The amino acids in red signify
the divergence from the normal protein.
(D) RT-PCR was performed using RNA derived
from ALS patients with the indicated LOF variant
or without (controls) using primers to amplify either
both wild-type (155 bp) and mutant (127 bp) splice
forms or specifically the mutant splice form (80 bp,
right panel). The arrow represents the position of
the mutant-specific product. The tick marks
represent 200 bp (upper) and 100 bp (lower)
markers.patients with uncomplicated types of hereditary spastic parapa-
resis and CMT2 display a normal life expectancy (Patzko´ and
Shy, 2011).
DISCUSSION
We previously identified KIF5A as a candidate gene for ALS in
our prior study that lacked the power to draw a definitive conclu-
sion (Kenna et al., 2016). KIF5A was also a candidate ALS gene
in a previous GWAS, though it similarly failed to reach genome-
wide significance (McLaughlin et al., 2017; van Rheenen et al.,
2016), as well as a single gene study selected based on the a
priori knowledge of its role in HSP/CMT2 and cytoskeletal func-
tion (Brenner et al., 2018). Here, we have confirmed KIF5A as an
ALS-associated gene with genome-wide significance through
two independent approaches. By performing a GWAS involving
80,000 samples, in addition to replicating five previously pub-
lished loci, as well as the previously reported locus SCFD1 using
a linear mixed model analysis (data not shown), we identified a
missense variant within the KIF5A gene that reached genome-
wide significance for association with ALS risk. It should be
stated though, that as with all GWASs, we cannot rule out
that other variants in linkage disequilibrium represent the pri-
mary risk factor. In an independent line of investigation, we
applied RVB to exome sequencing of 21,000 samples and
identified an exome-wide significant association between
FALS risk and rare KIF5A LOF variants. Analyses of KIF5A in in-
dependent replication cohorts both confirmed our initial finding
for the p.Pro986Leu variant and revealed three additional car-
riers of LOF variants in 9,046 ALS cases. Taken together, our re-
sults indicate that the p.Pro986Leu KIF5A variant may representNea relatively common, but low penetrance,
risk allele for ALS, while LOF variants
constitute rare, but high penetrance,
risk factors.Kinesins are microtubule-based motor proteins involved in
intracellular transport of organelles within eukaryotic cells. In
mammals, there are three heavy-chain isoforms of KIF5:
KIF5A, KIF5B, and KIF5C (Miki et al., 2001). The three proteins
homo- and heterodimerize through their coiled-coiled stalk
domain, and create a complex with two kinesin light chains
via binding to the tail domain (Hirokawa et al., 1989). All three
KIF5 genes are expressed in neurons (Kanai et al., 2000) and
function to transport many cargos by binding to distinct adaptor
proteins.
The central role of kinesins in axonal transport leads us to
speculate that mutations in KIF5A cause disease by disrupting
this process. Indeed, defects in axonal transport are a common
observation in ALS patients and are already known to directly
contribute to motor neuron degeneration pathogenesis (Cheva-
lier-Larsen and Holzbaur, 2006; Hirokawa et al., 2010; Mille-
camps and Julien, 2013). KIF5 mediates the transport of gran-
ules containing both RNA and RNA-binding proteins within
neuronal dendrites and axons (Kanai et al., 2004). Among these
cargos are the ALS-associated proteins FUS and hnRNPA1 (Guo
et al., 2017; Kim et al., 2013; Kwiatkowski et al., 2009; Vance
et al., 2009). Similarly, KIF5 mediates the transport of VAPB
through the adaptor protein protrudin (Matsuzaki et al., 2011),
and mutations in the VAPB gene have been identified in ALS
and late-onset spinal muscular atrophy (Nishimura et al., 2004,
2005). KIF5 is responsible for the axonal transport of neurofila-
ments (Wang and Brown, 2010) and KIF5A knockout mice
display abnormal transport of neurofilaments (Xia et al., 2003).
Abnormal accumulation of neurofilaments is a pathological hall-
mark of ALS and rare mutations in neurofilament heavy polypep-
tide (NEFH) are associated with ALS (Al-Chalabi et al., 1999).uron 97, 1268–1283, March 21, 2018 1277
SPG10/CMT2
p.Y63C, p.D73N, p.R162W, p.M198T, 
p.S202N, p.S203C, p.R204Q, 
p.R204W, p.V231L, p.D232N, p.G235E, 
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p.N256S, p.K257N, p.S258L, p.L259Q, 
p.Y276C, p.P278L, p.R280H, p.R280C, 
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Figure 5. KIF5A ALS Mutations Show
Distinct Localization from Missense Muta-
tions Previously Associated with SPG10
and CMT2
Causative mutations for SPG10 and CMT2
described within the literature (Crimella et al.,
2012; Jennings et al., 2017; Liu et al., 2014; Reid
et al., 2002) and ALS-associated mutations iden-
tified within this study are shown. As illustrated,
mutations causative for SPG10/CMT2 are pre-
dominantly missense changes located in the
N-terminal motor domain. In contrast, ALS muta-
tions are primarily located at the C-terminal motor
domain and are LOF. The double asterisk denotes
the risk variant identified through the GWAS.KIF5 also contributes to the transport of mitochondria (Kanai
et al., 2000; Tanaka et al., 1998) and motor neurons derived
from KIF5A/ mice display transport deficits and reduced sur-
vival (Karle et al., 2012). Impaired transport and dysfunction of
mitochondria represent another common hallmark observed in
ALS patients (Chevalier-Larsen and Holzbaur, 2006; Guo et al.,
2017; Palomo and Manfredi, 2015; Smith et al., 2017). KIF5
also contributes to the transport of AMPA-type (Heisler et al.,
2014; Setou et al., 2002) and GABAA receptors (Nakajima
et al., 2012). In keeping with reported ALS genes such as
NEK1 (Thiel et al., 2011) and PFN1 (Wu et al., 2012), modulation
of KIF5A expression has been shown to influence the formation
of neurite-like membrane protrusions (Matsuzaki et al., 2011).
Given its critical interactions with the cytoskeleton, the identifica-
tion of KIF5A mutations further extends the list of cytoskeletal-
related proteins implicated in ALS pathogenesis, such as
PFN1, TUBA4A, NEFH, and peripherin (Al-Chalabi et al., 1999;
Gros-Louis et al., 2004; Smith et al., 2014; Wu et al., 2012).
An important question raised by the current study is why vari-
ation within the C-terminal cargo-binding domain is associated
with ALS, while missense variations of the N-terminal motor
domain are associated with hereditary spastic paraparesis and
CMT2. Missense mutations within this latter domain have been
shown to affect microtubule binding and/or ATP hydrolysis, re-
sulting in a defective KIF5A-mediated anterograde transport of
cargo along dendrites and axons. This, in turn, leads to the
axonal retrograde degeneration observed both in hereditary
spastic paraparesis and CMT2, two length-dependent axonopa-
thies (Ebbing et al., 2008). In contrast, the primary cellular
lesion in ALS is believed to occur within motor neuron cell
bodies, where cytoplasmic protein aggregates are consistently
observed, and to propagate anterogradely along neurites. We
anticipate that LOF variants within the C-terminal domain of
KIF5A will disrupt binding with specific cargo proteins. This is
supported by a study in zebrafish in which truncation of the C ter-
minus resulted in a dramatic disruption of axonal localization of
mitochondria (Campbell et al., 2014). One possible mechanism
is that disruption of binding to cargo may possibly lead to their
accumulation and seed aggregation within the cell body, result-
ing in a deficiency at neurite terminals. Deficiency in KIF5A
expression and cargo binding has been associated with
accumulation of phosphorylated neurofilaments and amyloid
precursor protein within neuronal cell bodies, and subsequent
neurodegeneration, in patients with multiple sclerosis (Hares1278 Neuron 97, 1268–1283, March 21, 2018et al., 2017). While differences in KIF5A kinetics and KIF5A inter-
actions constitute one possibility to explain the phenotypic het-
erogeneity, it is also possible C-terminal and N-terminal variants
act through a common mechanism, but that a difference in the
relative extent of loss- or gain-of-function toxicities leads to
milder (i.e., hereditary spastic paraplegia or CMT2) or more se-
vere (i.e., ALS) phenotypes.
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HiSeq X Ten Reagent Kit Illumina Cat# FC-501-2501
Oligonucleotides
F1 primer sequence: CAGTGGAGCCACATCTTCTG Operon Technologies N/A
R1 primer sequence: TCTCTTGGTGGAGAGGGAAA Operon Technologies N/A
F2 primer sequence: CCAACATGGACAATGGAGTGA Operon Technologies N/A
Software and Algorithms
ASSEDA Tompson et al., 2007 http://www.cytognomix.com/?post_
type=duka&p=2670
BWA Wellcome Trust Sanger Institute http://bio-bwa.sourceforge.net
GenABEL The GenABEL Project http://www.genabel.org
GATK Broad Institute https://software.broadinstitute.org/gatk/
id_geno_checksum Broad Institute https://personal.broadinstitute.org/sripke/
share_links/checksums_download/
KING Manichaikul et al., 2010 http://people.virginia.edu/wc9c/KING/
LASER University of Michigan http://csg.sph.umich.edu/chaolong/LASER/
Mach2dat Marchini and Howie, 2010 https://genome.sph.umich.edu/wiki/
Mach2dat:_Association_with_MACH_output
METAL Willer et al., 2010 http://csg.sph.umich.edu/abecasis/metal/
index.html
Minimac3 Das et al., 2016 https://genome.sph.umich.edu/wiki/Minimac3
PLINK Chang et al., 2015 http://zzz.bwh.harvard.edu/plink/
R R Core Team https://www.r-project.org
SHAPEIT Delaneau et al., 2013 https://mathgen.stats.ox.ac.uk/genetics_
software/shapeit/shapeit.html
dbNSFP Liu et al., 2013 http://varianttools.sourceforge.net/
Annotation/DbNSFP
Other
Genotyped data Current paper https://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?study_id=
phs000101.v4.p1
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John
Landers (john.landers@umassmed.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study cohorts
GWAS cohort I
We undertook a GWAS of patients diagnosed with ALS (case cohort) and neurologically normal control individuals (control cohort).
DNAwas extracted from either whole blood or frozen brain tissue samples using standard procedures. All 12,663 patients included in
the case cohort had been diagnosedwith ALS according to the El Escorial criteria (Brooks, 1994) by a neurologist specializing in ALS,
had onset of symptoms after age 18 years, and were of non-Hispanic white race/ethnicity. Both patients with familial ALS and
patients with sporadic ALS were included in the analysis.
For the control cohort, we used genotype data obtained from (a) the database of Genotypes and Phenotypes (dbGaP) web repos-
itory (n = 44,017 US samples); (b) the HYPERGENES Project (n = 887 Italian samples) (Salvi et al., 2012); and (c) the Wellcome Trust
Case Control Consortium (n = 5,663 British samples). An additional 2,112 US and Italian control samples were genotyped in the Lab-
oratory of Neurogenetics, National Institute on Aging. The control cohort was matched to the case cohort for race and ethnicity, but
not for age or sex. A detailed description of the cohorts is available in Tables S1 and S2.
Written consent was obtained from all individuals enrolled in this study, and the study was approved by the institutional review
board approval of the National Institute on Aging (protocol number 03-AG-N329).
GWAS cohort II
Summary statistics from a recently published GWAS based on logistic regression analysis involving 12,577 cases and 23,475
controls were downloaded from the Project MinE Variant Browser. Additional details of the cohorts used in this study are available
in van Rheenen et al. (2016).
FALS discovery cohort
A total of 1,463 FALS patients were included in the initial cohort (pre-QC). Patients were recruited at specialist clinics in Australia
(n = 92), Belgium (n = 13), Canada (n = 34), Germany (n = 228), Ireland (n = 18), Israel (n = 26), Italy (n = 230), Netherlands
(n = 50), Spain (n = 60), Turkey (n = 72), UK (n = 223), and USA (n = 417). All samples were exome sequenced except those from
the Netherlands which were whole genome sequenced. Familial history was considered positive for ALS if the proband had at least
one affected relative within three degrees of relatedness.
Control discovery cohort
Read level sequencing data were obtained from dbGAP and the European Genome-Phenome Archive (EGA) and are listed in
Table S5.
ALS WXS/WGS replication cohort
Replication analyses included sequencing data for a further 9,046 ALS cases and 1,955 non-ALS controls that were not also repre-
sented in the FALS discovery set. These samples included 2,742 cases subjected to WXS by the ALS Sequencing Consortium, as
described previously (Cirulli et al., 2015); 719 cases subjected to WXS by the Laboratory of Neurogenetics, National Institute on
Aging; 307 cases and 296 controls subjected to WGS by the Laboratory of Neurogenetics, National Institute on Aging; 155 cases
subjected to WGS by the CReATe Consortium; 1,017 cases subjected to WGS by the NYGC ALS Consortium, Genomic Translation
for ALS Care (GTAC) Consortium and Answer ALS Foundation; and 4,100 cases and 1,659 controls subjected to WGS by the Project
MinE Sequencing Consortium.
All samples included in the case cohort had been diagnosed with ALS according to the El Escorial criteria (Brooks, 1994) by a
neurologist specializing in ALS. We received approval for this study from the institutional review boards of the participating centers,
and written informed consent was obtained from all patients (consent for research).
METHOD DETAILS
Data generation and pre-processing
Generation of SNP array callset
The case cohort (n = 12,663 samples) and part of the control cohort (n = 2,112) were genotyped in the Laboratory of Neurogenetics,
National Institute on Aging, using HumanOmniExpress BeadChips (version 1.0, Illumina, San Diego, CA) according to the manufac-
turer’s protocol. These SNP genotyping arrays assay 716,503 SNPs across the genome. Individual-level genotypes for these
samples are available on the dbGaP web portal (accession number phs000101.v4.p1). The remainder of the control cohort had
been previously genotyped on HumanOmni BeadChips (Illumina) as part of other GWAS efforts (Table S2). Analyses were confined
to the 595,692 autosomal SNPs that were common across the SNP genotyping arrays.Neuron 97, 1268–1283.e1–e5, March 21, 2018 e2
Generation of FALS case-control callset for exome-wide RVB discovery analysis
Exome sequencing of cases was performed as previously described (Kenna et al., 2016). Control exome sequences were generated
as described under the relevant dbGAP and EGA project accessions. Sequence reads were aligned to human reference GRCh37
using BWA (Burrows-Wheeler Aligner) and processed according to recommended Genome Analysis Toolkit’s (GATK) best practices
(https://software.broadinstitute.org/gatk/best-practices/). Joint variant detection and genotyping of all samples were performed us-
ing the GATK HaplotypeCaller. Variant quality control was performed using the GATK variant quality score recalibration method with
default filters. A minimum variant quality by depth (QD) score of 2 was also imposed and all genotypes associated with genotype
quality (GQ)< 20 were reset to missing. Variants were also excluded in the event of case or control call rates < 70% (post genotype
QC). Identified variants can be viewed through our web based ALS Variant Server (see link below).
Generation of ALS case-control callset for KIF5A replication analysis
Data for the KIF5A locus was extracted from all independently generated sequencing datasets and remapped to GRCh37. Variant
calling was performed using the GATK haplotype caller as described above. In addition to the KIF5A locus, data was also extracted
for a panel of 240,715 common variant sites and used to perform a single unified sample QC as described below.
Functional annotation of variants identified by WXS/WGS
Variant calls were assigned predicted functional consequences using snpEFF (Single Nucleotide Polymorphism Effect) (Cingolani
et al., 2012), dbNSFP (A Database of Human Non-synonymous SNVs and Their Functional Predictions and Annotations) (Liu
et al., 2013) and dbscSNV (database of splice site consequences of Single Nucleotide Variants) (Jian et al., 2014), which is incorpo-
rated into dbNSFP. Variants were classified as ‘‘loss of function’’ (LOF) where the sequence change was predicted to encode a pre-
mature stop codon, a frameshift causing insertion-deletion or a splice site disrupting SNV. Variants were classified as potentially
splice altering if assigned an ‘‘ada’’ or ‘‘rf’’ score > 0.7 by dbscSNV. Splice variants of potential interest were further assessed for
putative effects on exon skipping using a secondary algorithm - automated splice site and exon definition server (ASSEDA) (Tompson
et al., 2007).
RT-PCR Analysis
Total RNA was prepared from lymphoblast lines using Trizol reagent. Reverse transcription using Applied Biosystems RNA to cDNA
kit (# 4368814) was performed with 0.5 mg with RNase inhibitor in a 20 ml reaction according to the manufacturer’s protocol. PCRwas
carried out using New England Biolabs One Taq Hot Start DNA Polymerase (# M0481S), 2 ml RT reaction (representing 50 ng input
RNA) and forward and reverse primer (0.15 mM each) in a 20 ml reaction volume. Amplification conditions were as follows: 94C for
30 s, {94C for 20 s, 58C for 20 s, 68C for 1minute} x 35 cycles, followed by an extension stage of 68C for 5minutes and a 4C hold.
Amplification of both normal and mutant splice forms used primers F1 (CAGTGGAGCCACATCTTCTG) and R1 (TCTCTTGGTGGA
GAGGGAAA). Primers used for the specific amplification of the mutant splice form were F2 (CCAACATGGACAATGGAGTGA), which
spans exons 26 and 28, and R1.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
Analysis of SNP array genotypes
Standard quality-control procedures were applied to our genotype data using PLINK software package (version 1.9) (Chang et al.,
2015), and a summary of the workflow is shown in Figure S1. We excluded samples that demonstrated: call rates of less than
97.5%; non-European ancestry; abnormal F inbreeding coefficient; mismatch between phenotypic and genotypic gender; or, cryptic
relatedness defined as identity-by-descent proportion of inheritance (pi_hat from PLINK) greater than 0.125. Samples in common
between our study and van Rheenen’s study were identified using the checksum program id_geno_checksum and were removed
from our analyses. We excluded palindromic SNPs, as well as SNPs with: call rates less than 95% in the US and Italian cohorts
or less than 99% in the UK, French and Belgium cohorts; minor allele frequency less than 0.05 in the control cohorts; Hardy-Weinberg
equilibrium P less than 107 in the US and Italian control cohorts and less than 105 in the UK, French and Belgium cohorts; miss-
ingness by case-control status P less than 105; or SNPs associated between the UK and French control cohorts with P less than
5.0x108. After quality control, 8,229 case and 36,329 control samples were included in the analysis, and 436,746 SNPs were avail-
able for imputation in the USA and Italy cohorts, and 420,131 SNPs were available in the UK, French and Belgium cohorts.
Estimation of the haplotypes was performed with SHAPEIT (version 2.r790) (Delaneau et al., 2013). Imputation was performed for
individual batches based on ethnicity using the 1000Genomes Project dataset (phase 3, version 5a, release 2013-05-02, http://www.
internationalgenome.org/) as reference and using Minimac3 software (version 1.0.11) (Das et al., 2016) with default settings. After
imputation, principal components were calculated using PLINK software after removing known hypervariable regions and the
1 MB surrounding the C9orf72 region. After analysis of the Scree plots, 2 to 4 principal components were retained per cohort as co-
variates in the association analyses to compensate for any residual population stratification.
Logistic regression was performed per batch usingmach2dat software (version 1.0.24) (Marchini and Howie, 2010) incorporating 2
to 4 principal components, age and gender as covariates, with dosage of imputed SNPs selected based on a Minimac3 R2 value of
imputation accuracy greater than 0.3. SNPs with an absolute beta coefficient value above 5 or with a minor allele frequency lesse3 Neuron 97, 1268–1283.e1–e5, March 21, 2018
than 0.01 were excluded frommeta-analysis. Meta-analysis was then performed combining the association results of the 13 batches
of our individual-level studies with van Rheenen’s study summary statistics using METAL software (version 2011-03-25) (Willer et al.,
2010) under an inverse-weighted, fixed effect model. A threshold P of 5.0 3 108 was set for genome-wide significance after Bon-
ferroni correction for multiple testing in the GWAS (Pe’er et al., 2008).
The programming code used to analyze these data is freely available on GitHub (https://github.com/AudeDN/ALS_GWAS_
1000G_mach2dat_2017), and GWAS summary statistics results for all tested SNPs are available from https://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000101.v4.p1.
Analysis of WXS/WGS genotypes
For both the discovery and replication phases, samples were excluded from the study in the event of failing to meet standard geno-
type call rate, heterozygosity, duplication, relatedness or population stratification filters as summarized in Table S6. Each of these
filters was performed using a set of autosomal markers meeting all of the following criteria: call rate > 0.95, minor allele frequency
(MAF) > 0.01, p > 0.001 for deviation from Hardy-Weinberg equilibrium, linkage disequilibrium pruning (R2 < 0.5, window size =
50, step = 5). Filtering of autosomal markers, sample call rate assessments and sample heterozygosity assessments were performed
using PLINK software. Study duplicates and sample relatedness within the WXS/WGS cohorts was identified using KING software
(Manichaikul et al., 2010). Study duplicates between WXS/WGS cohorts and GWAS datasets were identified using the checksum
program id_geno_checksum. LASER was used to generate PCA coordinates for samples from the Human Genome Diversity Panel
(HGDP). Samples from the FALS discovery cohort were then mapped to this reference co-ordinate space. The discovery cohort was
restricted to cases and controls occurringwithin 3 standard deviations of themean for EuropeanHGDP samples along principal com-
ponents 1-4.
RVB analyses were performed by penalized logistic regression of case-control status with respect to number of minor alleles
observed per sample per genewith andMAF < 0.001. Analyses were only performedwhere the dataset containedmore than 3 variant
allele occurrences. Replication analyses of rs113247976were performed using the same logistic regression protocol as used for RVB
analyses. All analyses were conditioned on the first 4 eigenvectors generated by principal components analysis of common variant
profiles. Genomic inflation factors were calculated using genome-wide association analysis for quantitative, binary and time-till-
event traits using GenABEL software. Candidate associations were tested for signs of call-rate or subcohort biases as outlined in
Figures S6 and S7. Meta-analysis of rs113247976 association results between sequencing and GWASwas performed usingMETAL.
Unless otherwise indicated, all statistical analyses were performed using R (version 3.2.0).
Control-control analyses
To identify genes potentially subject to confounding biases in FALS RVB analyses and to assess the potential impact of batch effects
with non-ALS-related data, population or phenotypic stratifiers, the control sample cohort was divided into 28 pseudo case-control
groups based on the sequencing center or associated dbGaP / EGA project (Table S5). Genes shown in gray achieve for possible
confounder association. Loci achieving a minimum p < 1 3 103 were deemed as displaying possible association with non-ALS
related batch effects.
DATA AND SOFTWARE AVAILABILITY
Datasets
The programming code used to analyze the GWAS data including the imputation with SHAPEIT and Minimac3, individual-based as-
sociation analysis using Mach2dat and a meta-analysis using METAL is freely available on GitHub: https://github.com/AudeDN/
ALS_GWAS_1000G_mach2dat_2017). GWAS summary statistics results for all tested SNPs and identified SNVs from our 1,138
FALS cohort used for the RVB analysis can be viewed through our web based ALS Variant Server (http://als.umassmed.edu). For
each variant, information on over 50 annotation fields and the results can be downloaded directly into Excel. The accession number
for the genotyped data reported in this paper is dbGaP: phs000101.v4 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.
cgi?study_id=phs000101.v4.p1).
Data Resources and Databases
1000 Genomes Project dataset: http://www.internationalgenome.org
Database of Genotypes and Phenotypes (dbGaP): https://www.ncbi.nlm.nih.gov/gap
dbNSFP: https://sites.google.com/site/jpopgen/dbNSFP
dbscSNV: incorporated into dbNSFP (see previous link).
European Genome-phenome Archive (EGA): https://ega-archive.org
HapMap project: http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html.
Human Genome Diversity Panel (HGDP): http://www.hagsc.org/hgdp/
HYPERGENES Project: https://cordis.europa.eu/project/rcn/86758_en.html
Project MinE Variant Browser: http://databrowser.projectmine.com
snpEFF: http://snpeff.sourceforge.net/SnpEff.html
Wellcome Trust Case Control Consortium: https://www.wtccc.org.uk/Neuron 97, 1268–1283.e1–e5, March 21, 2018 e4
Software
ASSEDA: http://www.cytognomix.com/?post_type=duka&p=2670
BWA: http://bio-bwa.sourceforge.net
GenABEL: http://www.genabel.org
GATK: https://software.broadinstitute.org/gatk/
id_geno_checksum: https://personal.broadinstitute.org/sripke/share_links/checksums_download/
KING: http://people.virginia.edu/wc9c/KING/
LASER: http://csg.sph.umich.edu/chaolong/LASER/
Mach2dat: https://genome.sph.umich.edu/wiki/Mach2dat:_Association_with_MACH_output
METAL: http://csg.sph.umich.edu/abecasis/metal/index.html
Minimac3: https://genome.sph.umich.edu/wiki/Minimac3
PLINK: http://zzz.bwh.harvard.edu/plink/
R: https://www.r-project.org
SHAPEIT: https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.htmle5 Neuron 97, 1268–1283.e1–e5, March 21, 2018
